Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
perflutren lipid microspheres
- Development stage
- Phase 4
- Lead developer
- Lantheus
- Modality
- Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Perflutren lipid microspheres are an ultrasound contrast agent formulated as a microbubble injectable suspension for intravenous administration. This agent is used in patients with suboptimal echocardiograms to enhance the visualization of cardiac structures. It works by opacifying the left ventricular chamber and improving the delineation of the left ventricular endocardial border. The suspension requires an activation process prior to use.
- Brand names
- Definity
- Other names
- perflutren lipid microsphereoctafluoropropane microspheres
Beyond the preview
Go deeper on perflutren lipid microspheres.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on perflutren lipid microspheres.